Dr. Marcel Daadi is an expert in regulated translational research, especially in stem cell therapeutic applications for Parkinson’s disease and brain injuries. He discovered growth and differentiation conditions to direct human neural stem cells toward the dopaminergic lineage. This work produced two hallmark studies, both of scientific importance and therapeutic application for Parkinson’s disease.
In an industrial setting (NeuroSpheres Ltd. and Layton Biosciences Inc.), he developed therapeutic neural stem cell lines for clinical use in stroke, Parkinson’s disease and other diseases and injuries. He is involved in the development of the world’s first cryopreserved neural product manufactured under current Good Manufacturing Practices and transplanted into patients afflicted with stroke at Layton Biosciences Inc., Sunnyvale CA.
At the University of California San Francisco, he was involved in pivotal Investigational New Drug-enabling gene therapy non-human primate studies that allowed Avigen, Inc. to conduct clinical trials for treating patients with Parkinson’s disease. At Stanford University, he started and led the human embryonic stem cell program focused on developing therapeutic stem cell lines for treating ischemic stroke. He also discovered and patented a novel technique of engineering neural cells from pluripotent human embryonic stem cells that is currently in development for treating patients with stroke.
Dr. Daadi's current and future research is centered on the
of technologies to establish pluripotent stem cells, isolate self-renewable
multipotent NSCs and generate specific neuronal lineages, such as dopaminergic
neurons for treating Parkinson’s disease.
reprogramming and genome-editing technologies to model neurological disorders
in vitro and to understand mechanisms mediating disease development and
degenerative processes following injury or disease.
therapeutic stem cell lines in our current Good
Manufacturing Practices (cGMP) facility at the Southwest
National Primate Research Center.
development using nonhuman primates models of a variety of diseases and
applying cell delivery and multimodal molecular imaging techniques to monitor
the safety and efficacy..
engineering of NSCs to investigate the role of optogenetics on their fate after
grafting. These studies will help determine the mechanisms mediating stem cell
graft–host interactions in enhancing neuro-regeneration and restoring function.
Results from our studies are the foundation of translational
research aimed at repairing diseased or injured brain through transplantation
of highly purified NSCs or stimulation of endogenous repair mechanisms.
Hong H.,Daadi M.M. (2019). Generating Neural Stem Cells from iPSCs with Dopaminergic Neurons Reporter Gene.Methods Mol. Biol. 1919: 119-128.
Kim J.,Daadi M.M. (2019).Single-Cell Library Preparation of iPSC-derived Neural Stem Cells.Methods Mol. Biol.1919: 129-143.
Kim J.,Daadi M.M. (2019).Bioinformatics Analysis of Single-Cell RNA-Seq Raw Data From iPSC-Derived Neural Stem Cells.Methods Mol. Biol. 1919: 145-159.
Roy-Choudhury G.,Daadi M.M. (2019).Assay for Assessing Mitochondrial Function In iPSC-Derived Neural Stem Cells and Dopaminergic Neurons.Methods Mol. Biol.1919: 161-173.
Yang G., Hong H., Torres A., Malloy K.E., Choudhury G.R., Kim J., Daadi M.M. (2019). Reference Transcriptome for Deriving Nonhuman Primate Induced Pluripotent Stem Cells.Methods Mol. Biol. 1919: 175-186.
Hong H., Roy-Choudhury G., Kim J.,Daadi M.M. (2019).Isolation and Differentiation of Self-Renewable Neural Stem Cells from Marmoset Induced Pluripotent Stem Cells.Methods Mol. Biol. 1919: 199-204.
Choudhury G.R., Daadi M.M. (2018). Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease. PLoS One. 2018 Aug 23; 13(8):e0202770..
Yang G., Hong H., Torres A., Malloy K.E., Choudhury G.R., Kim J., Daadi M.M. (2018) Standards for Deriving Nonhuman Primate-Induced Pluripotent Stem Cells, Neural Stem Cells and Dopaminergic Lineage. (2018). Int J Mol Sci. 2018 Sep 17; 19(9).